Cerenome (CNSY) is trading at $2.00, up 7.53%, following a positive Q3 business update. * The company reported $1.55 million in unaudited Q3 gross billings from 222 tests, with initial cash collections anticipated in Q4. * Cerenome also announced a favorable preliminary CMS pricing decision for its CNSide PLA code and continued progress in expanding coverage to 158 million contracted lives.